Duke researchers have classified UGDH enzyme as an indicator of tumor progression across various cancers and a possible target for treatment.
The paper, which was published Sept. 28, 2023, in Oncotarget, concludes that while directly targeting UGDH might not be feasible as a standalone treatment, “it could be an important adjunct to current therapies. Furthermore, modulating its activity could help better understand mechanisms behind drug resistance and/or prevent resistance from developing.”
Rory Goodwin, MD, PhD, is the senior author of the paper. Other Duke-affiliated researchers include Annee D. Nguyen, Jovita K. Byemerwa, and Jasmine Flowers.